Evolving Treatment Strategies for Cervical Cancer

Nadeem Abu-Rustum, MD
Memorial Sloan Kettering Cancer Center

1. Surgery
2. Radiation
3. Chemotherapy
Surgery Generally for Stage I Cervical Cancer
FIGO stage IB1 (2-3cm adenoca)
Surgical Questions in Cervical Cancer 2016

1. Decrease radicality of resections
2. Sentinel lymph node (SLN) mapping
3. Neoadjuvant chemotherapy (area of active research not in NCCN guidelines)
   - Pre-Fertility sparing surgery
   - Pre-Radical hysterectomy
4. Improving QOL
   - Nerve Sparing Radical Hysterectomy
   - Minimally invasive surgery vs. Open
5. Surgical Staging in Advanced Stage

Changes in Surgical Approach Stage I 2001-2016

- Stage I Cervical Cancer
- Uterine Preservation
- Nodal Assessment
- Trachelectomy Vaginal 2001
- Abdominal 2004
- Conization 2005
- SLN 2003 Algorithm 2010
2013 NCCN Guidelines

CLINICAL STAGE  PRIMARY TREATMENT (FERTILITY SPARING)

Stage IA1

- Cone biopsy with negative margins
  (preferably a non-fragmented specimen with 3-mm negative margins)
  (if positive margins, rebiopsy or perform trachelectomy)

Stage IA1 (with LVSI)

- Cone biopsy with negative margins
  (preferably a non-fragmented specimen with 3-mm negative margins)

Stage IA2

- Radical trachelectomy + pelvic lymph node dissection
  + para-otic lymph node sampling
  + sentinel lymph node mapping

Stage IB1

- Radical trachelectomy
  + pelvic lymph node dissection
  + para-otic lymph node sampling
  + sentinel lymph node mapping

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

2014 NCCN Guidelines

CLINICAL STAGE  PRIMARY TREATMENT (FERTILITY SPARING)

Stage IA1

- Cone biopsy with negative margins
  (preferably a non-fragmented specimen with 3-mm negative margins)
  (if positive margins, rebiopsy or perform trachelectomy)

Stage IA1 (with LVSI)

- Cone biopsy with negative margins
  (preferably a non-fragmented specimen with 3-mm negative margins)
  (if positive margins, rebiopsy or perform trachelectomy)
  + para-otic lymph node dissection
  + sentinel lymph node mapping

Stage IB1

- Radical trachelectomy
  + pelvic lymph node dissection
  + para-otic lymph node sampling
  + sentinel lymph node mapping

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Copyright 2016©, National Comprehensive Cancer Network®. All rights reserved. No part of this publication may be reproduced or transmitted in any other form or by any means, electronic or mechanical, without first obtaining written permission from NCCN®.
Stage IA1 No Lymphovascular Invasion (LVI)

- Can be treated with Cone
- Review Pathology

---

Stage IA1 with LVI

SLN Mapping & Conization

SLN mapping is Category 2B recommendation

“Less is more….”
SENTICOL Study

- 139 patients
- Intraoperative radioisotope-blue dye mapping detected at least one SLN in 98%, 23 of whom had true-positive results and two who had false-negative results, yielding 92.0% sensitivity and 98.2% NPV.
- No false-negative results were observed in the 104 patients (76.5%) in whom SLN were identified bilaterally.
- SLN biopsy was fully reliable only when SLNs were detected bilaterally.

Lecuru F. JCO 2011

MSKCC SLN Mapping Algorithm (Category 2B)

- 122 patients were included. Median SLN count was 3 and median total LN count was 20.
- At least one SLN was identified in 93%
- Optimal (bilateral) mapping was achieved in 75% of cases.
- SLN correctly diagnosed 21 of 25 patients with nodal spread.
- When the algorithm was applied, all patients with LN metastasis were detected
- With optimal mapping, bilateral pelvic LND could have been avoided in 75% of cases.

Cormier B. et al. Gynecol Oncol 2011
**NCCN Guidelines Version 1.2016**

**Cervical Cancer**

**PRINCIPLES OF EVALUATION AND SURGICAL STAGING WHEN SLN MAPPING IS USED**

The key to a successful SLN mapping (category 2B) is the adherence to the SLN algorithm, which requires the performance of a side-specific nodal dissection in cases of failed mapping and removal of any suspicious or grossly enlarged nodes regardless of mapping (Figure 3).

*Figure 3: Surgical SLN Mapping Algorithm for Early-Stage Cervical Cancer*

- Excision of all mapped SLN
- Any suspicious nodes must be removed regardless of mapping
- If there is no mapping on a hemi-pelvis, a side-specific LND is performed
- Paravaginal resection is performed en bloc with a resection of the primary tumor

---

**Sentinel Lymph Node Mapping for Cervical Cancer**

- SLN mapping as part of the surgical management of select stage I cervical cancer is considered in gynecologic oncology practices worldwide. While this technique has been used in tumors up to 4 cm in size, the best detection rates and mapping results are in tumors less than 2 cm. This simple technique utilizes a direct cervical injection with dye or radiocolloids Technetium-99 (99Tc) into the cervix, usually at 2 or 4 points as shown in Figure 1. The SLNs are identified at the time of surgery with direct visualization of colored dye, a fluorescent camera if indocyanine green (ICG) was used, or a gamma probe if 99Tc was used. SLNs following a cervical injection are commonly located medial to the external iliac vessels, ventral to the hypogastric vessels, or in the superior part of the obturator space. (Figure 2). SLNs usually undergo ultrastaging by pathologists, which allows for higher detection of micrometastasis that may alter postoperative management.

*Figure 1: Options of SLN Cervical Injection Sites*  
*Figure 2: SLNs (blue, arrow) After Cervical Injection Are Commonly Located Medial to the External Iliac, Ventral to the Hypogastric, or in the Superior Part of the Obturator Space*

---

*Figures 1 and 2 are reproduced with permission from Memorial Sloan Kettering Cancer Center. © 2013 Memorial Sloan Kettering Cancer Center.*

---

© 2016 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN®. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.
Stage IA2

cancer invasion is 3-5 mm deep and < 7 mm wide

Stage IB1
- Radical Abdominal (Wertheim) Hysterectomy
- Radical Vaginal (Schauta) Hysterectomy
- Complete Bilateral Pelvic Lymphadenectomy +/- Paraortic Lymph Node Sampling
Type B Radical Resection

Endocervical Margin Vaginal Trachelectomy
Type C Radical Resection

Parametrectomy

We recommend exercising caution when considering abbreviation of parametrectomy and based on our data we continue to include this procedure in our surgical algorithm for the majority of stage IB1 cervical cancers
Oncologic Outcome of Radical Trachelectomy vs. Radical Hysterectomy for Stage IB1 Cervical Cancer

MSKCC Survival Data


3 & 9 O’clock: 1cc superficial on each side

Abu-Rustum. Atlas of Procedures in Gynecologic Oncology
Colored Dye: Simple Setup

Optimal Mapping
SLN Left External Iliac Lymph Node

Most Common Drainage
ICG – Color Segmented Fluorescence
**SLN Future Directions**

**Fertility-Sparing Surgery in Stage I Cervical Ca**

- **For bigger lesions with no obvious metastasis by imaging:**
  - SLN Algorithm
  - If (-)SLN → Neoadjuvant chemotherapy followed by radical trachelectomy or conization

- **For smaller lesions:**
  - SLN Algorithm
  - if (-) SLN → conization or simple trachelectomy

- **For high-risk resected lesions:**
  - Adjuvant chemotherapy, instead of radiation+chemo

---

**Challenges in Surgical Research**

**Availability of Expertise - Feasibility**

- Nerve sparing surgery
- Trachelectomy
- SLN
- Laparoscopy & Robotic in developing world

**Patient Access & Funding**

- Majority of cervical cancers in developing world
Select Current Surgical Studies

1) GOG #278-Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer
2) GCIG Shape Trial- Radical Versus Simple Hysterectomy and Pelvic Node Dissection in Patients With Low-risk Early Stage Cervical Cancer
3) Uterus11- Surgical Staging in Cervical Cancer Prior to Chemoradiation
4) LACC- Laparoscopic Approach to Cervical Cancer

NCCN Framework™
For Resource Stratification of NCCN Guidelines

Includes essential services needed to provide basic minimal standard of care.

NCCN Framework™
For Resource Stratification of NCCN Guidelines

Includes services that provide major improvements in disease outcomes, eg, survival, that are not cost prohibitive.
NCCN Framework™
For Resource Stratification of NCCN Guidelines

This level includes additional services that provide lesser improvements in disease outcomes and/or services that provide major improvements in disease outcomes but are cost prohibitive at lower resource levels.

Chemotherapy & Radiation Trials

Primary Treatment
- Chemoradiation:
  - Chemoradiation & cisplatin schedule
  - Chemoradiation + Adjuvant chemo
  - Neoadjuvant chemo + Chemoradiation
- Adjuvant Radiation:
  - Post op high risk
  - Post op intermediate risk

Palliative RT
NACT (Neoadjuvant Chemotherapy)
Not currently an NCCN Guideline

1. Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer (INTERLACE) UK
2. Neoadjuvant Chemotherapy Followed by Surgery Vs. Chemoradiation in Carcinoma of the Cervix (NACTcervix) India
3. Neoadjuvant Chemotherapy Followed by Radical Hysterectomy Vs. Primary Chemo-radiation in FIGO Stage IB2 - IIB (NACOPRAD) Germany
4. Neoadjuvant Chemotherapy and Radical Surgery in Stage IIB Cervical Cancer (SYSGO002) China
5. Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix. (CIRCE) Brazil

A trial of chemotherapy before chemoradiation for cervical cancer (INTERLACE)

- This trial is looking at giving carboplatin and paclitaxel before chemoradiation for cervical cancer that cannot be removed with surgery.
- This trial is supported by Cancer Research UK.

ClinicalTrials.gov: NCT01566240
A trial of chemotherapy before chemoradiation for cervical cancer (INTERLACE)

Randomise

Carboplatin AUC2 & Paclitaxel 80mg/m²
Weeks 1–6

Standard CRT

Weeks 7–13
Standard CRT

Follow-up
3 monthly for 2 years; 6 monthly for 3 years

Standard CRT: 40–50.4Gy in 20–28 fractions plus Intracavitary brachytherapy to give total dose of 78–86Gy to point A/volume. Weekly cisplatin 40mg/m² x 5 weeks

ClinicalTrials.gov: NCT01566240

INTERLACE Trial

Current status:
• 27 sites open to recruitment
• 83 patients recruited
• Target recruitment = 770

ClinicalTrials.gov: NCT01566240
**IMRT**
(Intensity-Modulated Radiation Therapy)

- Standard vs. IMRT in Endometrial or Cervical Cancer (Ann Klopp, USA)
- IMRT for Locally Advanced Cervical Cancer (Melanie Powell, UK)
- IMRT With Cisplatin Stage I-IVA Cervical Cancer (Loren Mell, USA)
- IMRT With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Ca (Loren Mell, USA)

**Hypofractionated Radiation Therapy**
(CCRN)

- Radiation treatment total dose is divided into larger doses/day and treatments are given once a day or less often.
- Radiation is delivered over a shorter period of time than standard therapy.
- Goal is to improve care delivery
- More practical
- Integration with chemo to be determined
- Toxicity to be determined
Adjuvant Chemotherapy after Chemoradiation

1. A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone (OUTBACK, Linda Mileshkin, AU)
2. ChemoRT with and without adjuvant chemotherapy in high risk cervix cancer after hysterectomy
   RTOG-0724 (GOG William Small)
3. Adjuvant Chemotherapy (TPx3) for Locally Advanced Cervical Cancer (Siriwan and Vichan, Thailand)
4. A Multicenter Trial of Benefits of Adding Post-surgery Chemotherapy (TP 2x2) for Cervical Cancer (Jihong Liu, China)

OUTBACK Trial

(ANZGOG 0902 / GOG 0274 / RTOG 1174)
NCT01414608
A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone

Principal Investigator: Prof Linda Mileshkin
OUTBACK Study Schema

Patients with stage IB1 & positive nodes, IB2, II, IIIA or IVA cervical cancer who have given informed consent

Eligible patients

RANDOMISE

Max 6 weeks

Weekly Cisplatin x5

Arm A - Control Arm
Concurrent chemoradiation

Arm B - Intervention Arm
Concurrent chemoradiation followed by adjuvant chemotherapy

4 weeks later
Paclitaxel+Carboplatin X4

Follow up for a minimum of 3 years

ClinicalTrials.gov: NCT01414608

Chemoradiation

Adjuvant:

• Randomized Phase III Clinical Trial of Adjuvant Radiation vs. Chemoradiation In Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy ;Sang Young Ryu, GOG 263-KGOG

Curative:

• Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer (TACO) (Sang Young Ryu, Korea)
TACO
(Tri-weekly Administration of Cisplatin in LOcally Advanced Cervical Cancer)
“the optimal cisplatin dose and dosing schedule are still undetermined”

Control Arm; Weekly Cisplatin
40mg/m2 6 cycles

Study Arm; Tri-weekly Cisplatin
75mg/m2 3 cycles

Cervical cancer
Locally advanced cervical cancer
Stage IB2, IIB-IVA

weekly cisplatin 40 mg/m2 considered to be a standard vs. tri-weekly cisplatin 75mg/m2 that may have lower toxicities and better outcomes

ClinicalTrials.gov: NCT01561586

NCCN Guidelines Version 1.2016 Cervical Cancer

CHEMOTHERAPY REGIMENS FOR RECURRENT OR METASTATIC CERVICAL CANCER
(Strongly consider clinical trial)

First-line combination therapy
- Cisplatin/paclitaxel/bevacizumab (category 1)
- Cisplatin/paclitaxel (category 1)
- Topotecan/paclitaxel/bevacizumab (category 1)
- Carboplatin/paclitaxel (Category 1 for patients who have received prior cisplatin therapy)
- Carboplatin/paclitaxel/bevacizumab
- Cisplatin/topotecan
- Topotecan/paclitaxel
- Cisplatin/gemcitabine (category 3)

Possible first-line single-agent therapy
- Cisplatin (preferred as a single agent)
- Carboplatin
- Paclitaxel

Second-line therapy (Agents listed are category 2B unless otherwise noted)
- Bevacizumab
- Albumin-bound paclitaxel
- Docetaxel
- 5-FU (5-fluourouracil)
- Gemcitabine
- Ifosfamide
- Irinotecan
- Mitomycin
- Pemetrexed
- Topotecan
- Vinorelbine
Targeted Therapy

- Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
- A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)
  - Fiona Simpkins, USA
- The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial
  - Kathy Han, Canada
- Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer
  - Linda Duska, USA
- 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib (BIBF 1120) in Cervix Cancer. Ignace Vergote, Belgium
- Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers (VICORYX-2) Elke Jager, Germany

Targeted Therapy (completed)

- A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer
- Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer
- Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer
- Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer
- Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
Future Trials

- **Checkpoint Inhibitors/Immune Modulators**
  - Ipilimumab, an anti-CTLA-4 antibody
  - MEDI6469, an OX40 immune
  - MEDI4736, a PD-L1-targeting
  - Urelumab (BMS-663513), an anti-4-1BB/CD137 antibody
  - Lirilumab (BMS-986015), an anti-KIR
  - MK-4166, an anti-GITR antibody
  - MOXR0916, an anti-OX40 agonist antibody
  - MEDI6383, an OX40 agonist

- **Therapeutic Vaccines**
  - ADXS11-001, a vaccine against the E7 protein
  - pNGVL4a/E7 (Detox)/HSP70 DNA vaccine

- **Adoptive T Cell Therapy**